Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance
Reviews in Cardiovascular Medicine · 24.12.2025 · 26 (12)
DOI: 10.31083/rcm46181 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 24.12.2025. Verfasst von Syed Bukhari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21218, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized and underdiagnosed cause of heart failure (HF), encompassing both preserved (HFpEF) and reduced (HFrEF) ejection fraction phenotypes. Once identifiable only following a biopsy, the advent of bone scintigraphy has dramatically improved noninvasive detection and detected a higher community prevalence, particularly among older patients with unexplained left ventricular hypertrophy. ATTR-CA arises from misfolding of transthyretin (TTR), leading to amyloid fibril deposition within the myocardium, which impairs cardiac compliance, conduction, and output. This review explores the evolving epidemiology of ATTR-CA in HF, mechanisms of disease progression, and key features for screening, emphasizing clinical red flags, biomarkers, and imaging features. This review also addresses the nuanced role of guideline-directed medical therapy in this population, where neurohormonal agents may offer limited benefit or be poorly tolerated due to restrictive physiology and autonomic dysfunction. Crucially, the emergence of amyloid-specific therapies, including TTR silencers, stabilizers, and degraders, has transformed the therapeutic landscape, offering mortality and morbidity benefits that were previously unavailable. Early diagnosis and individualized management, integrating conventional and amyloid-targeted approaches, are essential to improving outcomes in this complex and increasingly treatable cardiomyopathy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21218, USA.
- Department of Internal Medicine, TidalHealth, MD 21801, USA.
- Department of Internal Medicine, St. Luke's Healthcare, Sellersville, PA 18960, USA.
ORCID-Profile: Syed Bukhari, Mohammad Hamza, Aslam Malik
Zitieren
APA
Bukhari, S., Hamza, M., & Malik, A. (2025). Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance. Reviews in Cardiovascular Medicine, 26(12). https://doi.org/10.31083/rcm46181
Vancouver
Bukhari S, Hamza M, Malik A. Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance. Reviews in Cardiovascular Medicine. 2025;26(12). doi:10.31083/rcm46181
BibTeX
@article{Bukhari2025,
author = {Bukhari, Syed and Hamza, Mohammad and Malik, Aslam},
title = {Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance},
journal = {Reviews in Cardiovascular Medicine},
year = {2025},
volume = {26},
number = {12},
doi = {10.31083/rcm46181}
}
EUVIMED